Conference: Alzheimer's Association International Conference (AAIC) 2026
Dates: July 12-15, 2026
Location: ExCeL London, UK
Theme: Building Bridges in Alzheimer's Research
The approval of lecanemab (Leqembi) and donanemab (Kisunla) has transitioned Alzheimer's disease from a single-target era into a combination therapy paradigm. At AAIC 2026, the EU/US CTAD Task Force highlighted combination therapy as the central strategic priority for the next decade of AD drug development[1]. As of early 2026, the AD drug development pipeline includes 24 combination therapy trials, representing the largest growth sector in the field[2].
This page covers the scientific rationale, active clinical programs, trial design considerations, and regulatory landscape for combination approaches in Alzheimer's disease.
Alzheimer's disease involves multiple concurrent pathological processes, and targeting only one mechanism has proven insufficient for robust disease modification[3][4]:
The EU/US CTAD Task Force has formally concluded that monotherapy — even with the most effective anti-amyloid agents — cannot address the full complexity of AD, and that combination strategies are necessary to achieve the level of disease modification required for meaningful clinical impact[6][7].
Combination therapy can produce three types of interaction[4:1][8]:
The success of combination therapy in cancer (checkpoint inhibitors + chemotherapy + targeted therapy) and HIV (triple antiretroviral therapy — HAART) provides a strong precedent[9][10]:
The anti-amyloid + anti-tau combination is the conceptually most compelling strategy, targeting both hallmark pathologies of AD[11][10:1]:
The DIAN-TU is the leading platform for testing anti-amyloid + anti-tau combinations in genetic forms of AD:
The E2814 tau ASO (developed by Ionis and Eisai) targets the MAPT gene to reduce tau production:
Multiple programs are testing anti-tau antibodies in combination with approved anti-amyloid agents:
| Combination | Company | Phase | Status |
|---|---|---|---|
| Semorinemab + lecanemab | Roche/Genentech | Phase 2 | Planning |
| E2814 + lecanemab | Ionis/Eisai | Phase 1/2 (DIAN-TU) | Enrolling |
| Zagotenemab + donanemab | Eli Lilly | Phase 2 | Planning |
Monitoring combinations requires tracking both pathologies independently:
Neuroinflammation accelerates disease progression independent of amyloid, and the neuroinflammatory response to amyloid clearance may limit the benefit of anti-amyloid monotherapy[12][13]:
TREM2 agonists represent the most advanced anti-inflammatory approach for combination with anti-amyloid therapy[12:1]:
| Program | Company | Mechanism | Phase |
|---|---|---|---|
| AL002 | Alector/AbbVie | Anti-TREM2 agonistic antibody | Phase 2 (INVOKE-2) |
| PY314 | Pyroneer/Takeda | TREM2 agonist | Phase 1 |
| HFF223 | Honce/Takeda | TREM2 agonist | Preclinical |
Mechanism: TREM2 signaling promotes microglial survival, proliferation, and beneficial phagocytosis. TREM2 agonism may:
AAIC 2026 expected updates: Phase 2 AL002 (INVOKE-2) results in TREM2 variant carriers, with planned combination cohorts with anti-amyloid agents.
The complement system is a compelling target for combination because complement-mediated synaptic pruning continues even after amyloid clearance[13:1]:
| Program | Company | Target | Phase |
|---|---|---|---|
| ANX005 (anifrolumab) | Annexon | Anti-C1q | Phase 1b/2 |
| ABvac-40 | Araclon | Anti-A beta 40 | Phase 1 |
| CT0550 | ClearPath | Complement modulator | Preclinical |
Rationale: ANX005 (anti-C1q) combined with anti-amyloid therapy may reduce synaptic complement-mediated pruning that continues even after amyloid clearance. Phase 1b data showed good safety and biomarker target engagement; Phase 2 combination study with lecanemab is planned.
GLP-1 receptor agonists address metabolic dysfunction and neuroinflammation through orthogonal mechanisms, making them logical combination partners:
An alternative to multi-drug combinations is the design of single molecules that hit multiple targets[4:2]:
Advantages:
Challenges:
A landmark 2024 Cell publication introduced a data-driven approach to combination therapy design using cell-type-specific transcriptomic networks[10:2]:
Approach: Integrated single-cell transcriptomics from SEA-AD and Allen Brain Cell Atlas with drug perturbation databases and electronic medical records from 1.4 million adults aged 65+ across six University of California health systems[13:2]
Identified combination: Letrozole (aromatase inhibitor, used for breast cancer) targeting disease-associated gene expression in glial cells + irinotecan (topoisomerase inhibitor, used for colon/lung cancer) targeting neuronal disease networks
Preclinical results:
AAIC 2026 expected updates: Validation studies in human tissue, biomarker correlates, and planning for Phase 1/2 trials.
The gold standard for testing combination contributions is the 2x2 factorial design[4:3]:
Drug B
Placebo Active
Placebo Placebo Drug B alone
A Drug A Both drugs
alone
This design allows:
Challenge: Requires 4x the sample size of a simple two-arm trial.
Platform trials enable efficient testing of multiple combinations with shared control arms[14]:
Biomarker-driven patient selection maximizes signal detection[2:1]:
Testing the same combination across multiple neurodegenerative diseases that share mechanisms:
| Phase | Strategy | Rationale |
|---|---|---|
| Phase 1 | Monotherapy dose-finding | Establish safety of individual components first |
| Phase 2 | Two-drug combination | Test synergy, identify optimal dose combinations |
| Phase 3 | Phase 2-optimal combination | Confirm efficacy with validated regimen |
A critical regulatory question is whether a combination constitutes a "combination product" under FDA regulations or is simply two separate drugs used together[14:1]:
The FDA's accelerated approval pathway is particularly relevant for combinations[2:2]:
| Trial | Agents | Phase | Patients | Primary Endpoint | Status |
|---|---|---|---|---|---|
| INVOKE-2 | AL002 + lecanemab | Phase 2 | 300 | Biomarker + cognitive | Enrolling |
| AL002-001 | AL002 monotherapy | Phase 2 | TREM2 variant carriers | Safety + biomarkers | Ongoing |
| ANX005-Lecanemab | ANX005 + Leqembi | Phase 1b | 60 | Safety + target engagement | Planning |
| Trial | Agents | Phase | Patients | Primary Endpoint | Status |
|---|---|---|---|---|---|
| DIAN-TU | E2814 + lecanemab | Phase 1/2 | 180 | CSF tau + cognition | Enrolling |
| TRAILBLAZER-EXT | Donanemab + tau ASO | Phase 2 | 200 | Tau PET + CDR-SB | Planning |
| TAU-Combo | Semorinemab + lecanemab | Phase 2 | 400 | Biomarker + cognitive | Planning |
| Trial | Agents | Phase | Patients | Primary Endpoint | Status |
|---|---|---|---|---|---|
| COMBO-AD | Lecanemab + donepezil | Phase 4 | 500 | Cognitive + functional | Enrolling |
| SYMPHONY | Donanemab + memantine | Phase 4 | 300 | Safety + cognition | Enrolling |
| Trial | Regimen | Phase | Patients | Primary Endpoint | Status |
|---|---|---|---|---|---|
| STOP-AD | Lecanemab 18mo, then anti-inflammatory | Phase 2 | 250 | Clinical + biomarker | Enrolling |
| MAINTENANCE | Anti-amyloid → anti-tau maintenance | Phase 2 | 300 | Biomarker trajectory | Planning |
Combining anti-amyloid antibodies with other immunomodulatory agents may increase the risk of ARIA (amyloid-related imaging abnormalities)[15][16]:
Multi-drug combinations require assessment of pharmacokinetic and pharmacodynamic interactions:
Long-term combination therapy raises concerns about:
APOE genotype significantly impacts both disease risk and treatment response[@gillman2024]:
With the advent of blood-based biomarkers, precision combination selection is now feasible[@hansson2024]:
| Disease Stage | Recommended Combination |
|---|---|
| Preclinical (biomarker-positive, asymptomatic) | Single anti-amyloid or GLP-1 agonist; combinations may be overtreatment |
| Prodromal (MCI, biomarker-positive) | Anti-amyloid + symptomatic (if on AChEI) |
| Mild dementia | Anti-amyloid + anti-tau or anti-inflammatory |
| Moderate dementia | Combination with symptomatic agents; disease modification may have limited impact |
CTAD 2025 Conference — EU/US Task Force on Combination Therapy. 2025. ↩︎
Cummings JL, et al. Alzheimer's disease drug development pipeline: 2025. Alzheimer's & Dementia. 2025. ↩︎ ↩︎ ↩︎
Rochfort KD, et al. Combination Therapy for Neurodegenerative Diseases: A Systematic Review. Journal of Neurochemistry. 2023. ↩︎
Huang Y, et al. Multi-target Drug Design for Neurodegenerative Diseases. Nature Reviews Drug Discovery. 2022. ↩︎ ↩︎ ↩︎ ↩︎
Chen X, et al. Vascular Contributions to Alzheimer's Disease. Nature Reviews Neurology. 2023. ↩︎
Scheltens P, et al. Alzheimer's disease. Lancet. 2021. ↩︎
Milton N. Combination Therapy in Alzheimer's Disease: Current Status. CNS Drugs. 2021. ↩︎
Zhang L, et al. Synergistic Effects of Combination Therapy in Parkinson's Disease. Movement Disorders. 2022. ↩︎
Cummings JL, et al. Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia. 2024. ↩︎
Simmons DA, et al. Amyloid and Tau Dual Targeting for Alzheimer's Disease. Nature Reviews Neurology. 2023. ↩︎ ↩︎ ↩︎
Kaur G, et al. Neuroinflammation and Neuroprotection: Dual Therapeutic Approaches. Pharmacological Reviews. 2023. ↩︎ ↩︎
Wang Y, et al. TREM2 Biology and Therapeutic Targeting in Alzheimer's Disease. Nature Reviews Neuroscience. 2024. ↩︎ ↩︎
Bartels C, et al. Multi-omic Integration for Neurodegenerative Disease Biomarkers. Cell. 2023. ↩︎ ↩︎ ↩︎
Epelbaum S, et al. Combination Therapy in Alzheimer's Disease: The Way Forward. Lancet Neurology. 2025. ↩︎ ↩︎
van Dyck CH, et al. Lecanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023. ↩︎
Sims JR, et al. Donanemab in Early Alzheimer's Disease. New England Journal of Medicine. 2023. ↩︎